Research team airs messy truth about AI in medicine; Eli Lilly’s Mounjaro succeeds in second weight loss study

In public, hospitals rave about artificial intelligence. But on the frontlines, the hype is smashing into a starkly different reality.

April 27, 2023 Check out STAT+

Sponsored By

Mike Reddy for STAT A research team airs the messy truth about AI in medicine — and gives hospitals a guide to fix it A new report takes stock of how physicians, data scientists, and hospital leaders are struggling to harness AI tools in health care. By Casey Ross STAT+ | Eli Lilly's Mounjaro succeeds in second weight-loss study, paving way for FDA review Wall Street analysts expect the results to pave the way for approval of Mounjaro by the Food and Drug Administration. By Matthew Herper STAT+ | Health insurance CEOs set another record for pay in 2022 The CEOs of seven major health insurers together made more than $335 million in 2022. Molina's CEO brought in $181 million alone. By Bob Herman Courtesy Marcos Amend/Pulsar Imagens Vast sequencing project begins to unlock human genome's secrets — by deciphering other mammals' DNA The Zoonomia Project compared the genomes of 240 mammalian species to find DNA regions that remained mostly unchanged over 100 million years. By Jonathan Wosen STAT+ | Pharma executives shower Bill Cassidy with campaign cash Sen. Bill Cassidy's perch as the top Republican on the Senate health committee attracted campaign cash from pharma execs. By Rachel Cohrs and Sarah Owermohle Opinion: A judge's infuriating ruling on vaccination puts Mississippi's children at risk A judge's preliminary injunction requiring Mississippi to provide a religious exemption for vaccines puts the state's children at risk. By Dorit R. Reiss and Arthur L. Caplan Sammy Kimball for STAT Listen: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval This episode, STAT Europe correspondent Andrew Joseph joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated. By Damian Garde and Meg Tirrell and Adam Feuerstein STAT+ | Six months after launch, Bert Vogelstein's latest blood testing startup gets acquired for $450 million Quest announced that it is buying Bert Vogelstein's blood testing startup, which was founded by the founders of another blood testing startup By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser